Instelling

Vaccine and Infectious Disease Organization (VIDO)

1975-

Originally known as the Veterinary Infectious Disease Organization, VIDO was established at the University of Saskatchewan in 1975. VIDO is a research organization of the University of Saskatchewan that operates with financial support from the Government of Canada, the government of Saskatchewan, livestock industry councils and agencies, foundations and human and animal health companies. VIDO worked to find cures for common infectious diseases in cattle, swine and poultry. VIDO scientists carved out an international reputation for their pioneering work in the 1980's on vaccines aimed at combating shipping fever and a disease which produces pneumonia and arthritis in cattle. In addition to the 2,500,000 sq ft facility on campus, VIDO-InterVac also operates a 160-acre research station. The laboratory took on its current name, International Vaccine Centre (VIDO-InterVac), in March 2003. In October 2003 a large expansion was completed. In March 2004, VIDO received funding for the construction one of the world's largest and most advanced biosafety level 3 facilities, the International Vaccine Centre (InterVac), for research into emerging and reemerging human and animal diseases. In 2020, VIDO-InterVac began developing a vaccine for SARS-CoV-2 during the COVID-19 pandemic.

It was established with a grant provided by the Devonian Group of Charitable Foundations of Calgary, and with supplementary funding from the provincial governments of Alberta and Saskatchewan, the University, and subsequently a great many livestock and poultry organizations. VIDO represented a new and unique model for funding practical goal-oriented research, and established an international reputation by developing several new vaccines to prevent neonatal diarrhea, or scours, in newborn calves (Vicogen, Ecostar, Ecostar 2RC); Haemophilus somnus infection of cattle (Somnu-Star and Somu-Star Ph); shipping fever pneumonia in cattle (Pneumo-Star); pneumonia in pigs (Pleuro-Star); and adenovirus infection in turkeys (Hevlan-TC). It also developed new management and disease prevention programs for cattle and swine. In 2003, VIDO changed its name and opened an expansion to its building that now provides 80,000 square feet of ultramodern laboratory space for a staff of 145 researchers. It uses the most modern research tools of genomics and bioinformatics to develop new vaccines and vaccine delivery technology.

Stephen Acres

https://esask.uregina.ca/entry/vaccine_and_infectious_disease_organization_vido.jsp